Astellas, through its Mitobridge affiliate, has dosed the first patient in its pivotal Phase 2/3 clinical trial for ASP0367*, an oral investigational drug that may improve exercise intolerance and...

By Yoshitsugu Shitaka, President, Astellas Institute for Regenerative Medicine Astellas strives to be on the forefront of healthcare change and our work in regenerative medicine is a clear example...

By Bernhardt G. Zeiher, MD, FACP, FCCP, Chief Medical Officer The biopharmaceutical R&D enterprise is in the midst of a period of significant change and challenge. Over the last decade,...

By Effie Tozzo, PhD, Senior Vice President, Translational Sciences, Mitobridge, An Astellas Company Nov 8, 2019 Many of us know mitochondria as the energy suppliers of our cells. Given the myriad...

Dr. Dan Hoeppner, associate director of Neuroscience at the Astellas Research Institute of America (ARIA), appears in a new video released by the Pharmaceutical Research & Manufacturers of...

By Percival Barretto-Ko, President, Astellas Americas Nov 29, 2018 The U.S. Food and Drug Administration’s approval of XOSPATA® (gilteritinib) is a proud moment for Astellas. This approval is...

Mar 27, 2018 Allergies are a common part of everyday life, with symptoms ranging from mild discomfort at the onset of allergy seasons, to anaphylactic shock and death at exposure to certain foods....

Jan 24, 2018 Throughout his career, Salim Mujais has focused his work on one central goal: to make a difference in the world and people’s lives through science. As Senior Vice President and...

Oct 31, 2017 When it comes to innovation in cancer treatment, Astellas' oncology therapeutic area has a pioneering partner in Potenza Therapeutics, a privately held biotech company headquartered...

Apr 24, 2017 Aligned with our vision to turn innovative science into value for patients, Astellas has focused on exploring new therapeutic areas through a combined approach of homegrown science,...